MicroRNA‑4530 promotes angiogenesis by targeting VASH1 in breast carcinoma cells

Zhang,Tao; Jing,Li; Li,Hong; Ding,Linchao; Ai,Dongdong; Lyu,Jianxin; Zhong,Lianjin

doi:10.3892/ol.2017.6102

MicroRNA‑4530 promotes angiogenesis by targeting VASH1 in breast carcinoma cells

Authors:
- Tao Zhang
- Li Jing
- Hong Li
- Linchao Ding
- Dongdong Ai
- Jianxin Lyu
- Lianjin Zhong
View Affiliations

Affiliations: Key Laboratory of Laboratory Medicine, Ministry of Education, Zhejiang Provincial Key Laboratory of Medical Genetics, College of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, P.R. China
Published online on: April 28, 2017 https://doi.org/10.3892/ol.2017.6102
Pages: 111-118
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The results of our previous study revealed that microRNA (miRNA/miR)‑4530 was upregulated in the serum of patients with diabetic retinopathy. The TargetScan miRNA database was used to identify potential targets of miR‑4530 and vasohibin‑1 (VASH1) was predicted as one of the targets. The results of our previous study demonstrated that miR‑4530 was able to promote angiogenesis in human umbilical vein endothelial cells. Therefore, suppressing miR‑4530 may be a potentially novel approach towards inhibiting tumor angiogenesis. The present study aimed to investigate the function of miR‑4530 and determine whether miR‑4530 was able to regulate angiogenesis in breast carcinoma cells by targeting VASH1. MDA‑MB‑231 and MCF‑7 cells were transfected with miR‑4530 precursor, anti‑miR‑4530 and empty vector plasmids. The expression levels of miRNA and mRNA were detected using the reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR). The expression levels of protein were detected using western blotting. Dual‑luciferase reporter assays were used to identify the target of miR‑4530. Furthermore, cell proliferation, cell cycle, apoptosis and tube formation assays were used to investigate the function of miR‑4530 in vitro. Nude mice were used in a subcutaneous tumor model in vivo study. The results of the present study demonstrated that miR‑4530 significantly suppressed proliferation and promoted apoptosis of breast carcinoma cells. In addition, miR‑4530 expression promoted angiogenesis in vitro. Results from the western blotting and RT‑qPCR revealed that VASH1 was significantly downregulated by miR‑4530 in breast carcinoma cells. The results of the present study suggest that miR‑4530 promotes angiogenesis, inhibits proliferation and induces apoptosis in breast carcinoma cells by suppressing the expression of VASH1.

View Figures

View References

1	Shenouda SK and Alahari SK: MicroRNA function in cancer: Oncogene or a tumor suppressor? Cancer Metastasis Rev. 28:369–378. 2009. View Article : Google Scholar : PubMed/NCBI
2	Jovanovic M and Hengartner MO: miRNAs and apoptosis: RNAs to die for. Oncogene. 25:6176–6187. 2006. View Article : Google Scholar : PubMed/NCBI
3	Kent OA and Mendell JT: A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene. 25:6188–6196. 2006. View Article : Google Scholar : PubMed/NCBI
4	Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA. 103:pp. 2257–2261. 2006; View Article : Google Scholar : PubMed/NCBI
5	Yang G and Yin B: The advance of application for microRNAs in cancer gene therapy. Biomed Pharmacother. 68:137–142. 2014. View Article : Google Scholar : PubMed/NCBI
6	Zhou X, Xia Y, Li L and Zhang G: MiR-101 inhibits cell growth and tumorigenesis of Helicobacter pylori related gastric cancer by repression of SOCS2. Cancer Biol Ther. 16:160–169. 2015. View Article : Google Scholar : PubMed/NCBI
7	Zhang XF, Li KK, Gao L, Li SZ, Chen K, Zhang JB, Wang D, Tu RF, Zhang JX, Tao KX, et al: miR-191 promotes tumorigenesis of human colorectal cancer through targeting C/EBPβ. Oncotarget. 6:4144–4158. 2015. View Article : Google Scholar : PubMed/NCBI
8	Shen S, Guo X, Yan H, Lu Y, Ji X, Li L, Liang T, Zhou D, Feng XH, Zhao JC, et al: A miR-130a-YAP positive feedback loop promotes organ size and tumorigenesis. Cell Res. 25:997–1012. 2015. View Article : Google Scholar : PubMed/NCBI
9	Ding L, Ai D, Wu R, Zang T, Jing L, Lu J and Zhong L: Identification of the differential expression of serum microRNA in type 2 diabetes. Biosci Biotechnol Biochem. 80:461–465. 2016. View Article : Google Scholar : PubMed/NCBI
10	Watanabe K, Hasegawa Y, Yamashita H, Shimizu K, Ding Y, Abe M, Ohta H, Imagawa K, Hojo K, Maki H, et al: Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis. J Clin Invest. 114:898–907. 2004. View Article : Google Scholar : PubMed/NCBI
11	Kimura H, Miyashita H, Suzuki Y, Kobayashi M, Watanabe K, Sonoda H, Ohta H, Fujiwara T, Shimosegawa T and Sato Y: Distinctive localization and opposed roles of vasohibin-1 and vasohibin-2 in the regulation of angiogenesis. Blood. 113:4810–4818. 2009. View Article : Google Scholar : PubMed/NCBI
12	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using quantitative PCR and the 2-(Delta DeltaC(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
13	Giacco F and Brownlee M: Oxidative stress and diabetic complications. Circ Res. 107:1058–1070. 2010. View Article : Google Scholar : PubMed/NCBI
14	Du Y, Veenstra A, Palczewski K and Kern TS: Photoreceptor cells are major contributors to diabetes-induced oxidative stress and local inflammation in the retina. Proc Natl Acad Sci USA. 110:pp. 16586–16591. 2013; View Article : Google Scholar : PubMed/NCBI
15	Tang J and Kern TS: Inflammation in diabetic retinopathy. Prog Retin Eye Res. 30:343–358. 2011. View Article : Google Scholar : PubMed/NCBI
16	Hanahan D and Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:353–364. 1996. View Article : Google Scholar : PubMed/NCBI
17	Kerbel RS: Vasohibin: The feedback on a new inhibitor of angiogenesis. J Clin Invest. 114:884–886. 2004. View Article : Google Scholar : PubMed/NCBI
18	Shimizu K, Watanabe K, Yamashita H, Abe M, Yoshimatsu H, Ohta H, Sonoda H and Sato Y: Gene regulation of a novel angiogenesis inhibitor, vasohibin, in endothelial cells. Biochem Biophys Res Commun. 327:700–706. 2005. View Article : Google Scholar : PubMed/NCBI
19	Li D, Zhou K, Wang S, Shi Z and Yang Z: Recombinant adenovirus encoding vasohibin prevents tumor angiogenesis and inhibits tumor growth. Cancer Sci. 101:448–452. 2010. View Article : Google Scholar : PubMed/NCBI
20	Hosaka T, Kimura H, Heishi T, Suzuki Y, Miyashita H, Ohta H, Sonoda H, Moriya T, Suzuki S, Kondo T and Sato Y: Vasohibin-1 expression in endothelium of tumor blood vessels regulates angiogenesis. Am J Pathol. 175:430–439. 2009. View Article : Google Scholar : PubMed/NCBI
21	Yoshinaga K, Ito K, Moriya T, Nagase S, Takano T, Niikura H, Yaegashi N and Sato Y: Expression of vasohibin as a novel endothelium-derived angiogenesis inhibitor in endometrial cancer. Cancer Sci. 99:914–919. 2008. View Article : Google Scholar : PubMed/NCBI
22	Tamaki K, Moriya T and Sato Y, Nagase S, Takano T, Niikura H, Yaegashi N and Sato Y: Vasohibin-1 in human breast carcinoma: A potential negative feedback regulator of angiogenesis. Cancer Sci. 100:88–94. 2009. View Article : Google Scholar : PubMed/NCBI
23	Sato H, Abe T, Wakusawa R, Asai N, Kunikata H, Ohta H, Sonoda H, Sato Y and Nishida K: Vitreous levels of vasohibin-1 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Diabetologia. 52:359–361. 2009. View Article : Google Scholar : PubMed/NCBI
24	Shen J, Yang X, Xiao WH, Hackett SF, Sato Y and Campochiaro PA: Vasohibin is up-regulated by VEGF in the retina and suppresses VEGF receptor 2 and retinal neovascularization. FASEB J. 20:723–725. 2006.PubMed/NCBI
25	Yamashita H, Abe M, Watanabe K, Shimizu K, Moriya T, Sato A, Satomi S, Ohta H, Sonoda H and Sato Y: Vasohibin prevents arterial neointimal formation through angiogenesis inhibition. Biochem Biophys Res Commun. 345:919–925. 2006. View Article : Google Scholar : PubMed/NCBI
26	Heishi T, Hosaka T, Suzuki Y, Miyashita H, Oike Y, Takahashi T, Nakamura T, Arioka S, Mitsuda Y, Takakura T, et al: Endogenous angiogenesis inhibitor vasohibin1 exhibits broad-spectrum antilymphangiogenic activity and suppresses lymph node metastasis. Am J Pathol. 176:1950–1958. 2010. View Article : Google Scholar : PubMed/NCBI
27	Miyashita H, Watanabe T, Hayashi H, Suzuki Y, Nakamura T, Ito S, Ono M, Hoshikawa Y, Okada Y, Kondo T and Sato Y: Angiogenesis inhibitor vasohibin-1 enhances stress resistance of endothelial cells via induction of SOD2 and SIRT1. PLoS One. 7:e464592012. View Article : Google Scholar : PubMed/NCBI
28	Sato Y: Is vasohibin-1 for more than angiogenesis inhibition? J Biochem. 149:229–230. 2011. View Article : Google Scholar : PubMed/NCBI
29	Yan Y, Shen Z, Ye Y, Jiang K, Zhang H, Shen C, Mustonen H, Puolakkainen P and Wang S: A novel molecular marker of prognosis in colorectal cancer: Vasohibin-1. Med Oncol. 31:8162014. View Article : Google Scholar : PubMed/NCBI
30	Liu S, Han B, Zhang Q, Dou J, Wang F, Lin W, Sun Y and Peng G: Vasohibin-1 suppresses colon cancer. Oncotarget. 6:7880–7898. 2015. View Article : Google Scholar : PubMed/NCBI
31	Tamaki K, Sasano H, Maruo Y, Takahashi Y, Miyashita M, Moriya T, Sato Y, Hirakawa H, Tamaki N, Watanabe M, et al: Vasohibin-1 as a potential predictor of aggressive behavior of ductal carcinoma in situ of the breast. Cancer Sci. 101:1051–1058. 2010. View Article : Google Scholar : PubMed/NCBI